|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Osborne CK, Zhao H and Fuqua SA: Selective
estrogen receptor modulators: structure, function, and clinical
use. J Clin Oncol. 18:3172–3186. 2000.PubMed/NCBI
|
|
3
|
Harvey JM, Clark GM, Osborne CK and Allred
DC: Estrogen receptor status by immunohistochemistry is superior to
the ligand-binding assay for predicting response to adjuvant
endocrine therapy in breast cancer. J Clin Oncol. 17:1474–1481.
1999.PubMed/NCBI
|
|
4
|
Herynk MH and Fuqua SA: Estrogen receptors
in resistance to hormone therapy. Adv Exp Med Biol. 608:130–143.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ali S and Coombes RC: Endocrine-responsive
breast cancer and strategies for combating resistance. Nat Rev
Cancer. 2:101–112. 2002. View
Article : Google Scholar
|
|
6
|
Kurebayashi J: Endocrine-resistant breast
cancer: underlying mechanisms and strategies for overcoming
resistance. Breast Cancer. 10:112–119. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schiff R, Massarweh S, Shou J and Osborne
CK: Breast cancer endocrine resistance: how growth factor signaling
and estrogen receptor coregulators modulate response. Clin Cancer
Res. 9:447S–454S. 2003.PubMed/NCBI
|
|
8
|
Knowlden JM, Hutcheson IR, Jones HE,
Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE and Nicholson
RI: Elevated levels of epidermal growth factor receptor/c-erbB2
heterodimers mediate an autocrine growth regulatory pathway in
tamoxifen-resistant MCF-7 cells. Endocrinology. 144:1032–1044.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim S, Lee J, Lee SK, Bae SY, Kim J, Kim
M, Kil WH, Kim SW, Lee JE and Nam SJ: Protein kinase C-α
downregulates estrogen receptor-α by suppressing c-Jun
phosphorylation in estrogen receptor-positive breast cancer cells.
Oncol Rep. 31:1423–1428. 2014.
|
|
10
|
Benz CC, Scott GK, Sarup JC, Johnson RM,
Tripathy D, Coronado E, Shepard HM and Osborne CK:
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7
cells transfected with HER2/neu. Breast Cancer Res Treat. 24:85–95.
1992. View Article : Google Scholar
|
|
11
|
Li Z, Wang N, Fang J, Huang J, Tian F, Li
C and Xie F: Role of PKC-ERK signaling in tamoxifen-induced
apoptosis and tamoxifen resistance in human breast cancer cells.
Oncol Rep. 27:1879–1886. 2012.PubMed/NCBI
|
|
12
|
Martin MB, Franke TF, Stoica GE, Chambon
P, Katzenellenbogen BS, Stoica BA, McLemore MS, Olivo SE and Stoica
A: A role for Akt in mediating the estrogenic functions of
epidermal growth factor and insulin-like growth factor I.
Endocrinology. 141:4503–4511. 2000.PubMed/NCBI
|
|
13
|
deFazio A, Chiew YE, McEvoy M, Watts CK
and Sutherland RL: Antisense estrogen receptor RNA expression
increases epidermal growth factor receptor gene expression in
breast cancer cells. Cell Growth Differ. 8:903–911. 1997.PubMed/NCBI
|
|
14
|
Newby JC, Johnston SR, Smith IE and
Dowsett M: Expression of epidermal growth factor receptor and
c-erbB2 during the development of tamoxifen resistance in human
breast cancer. Clin Cancer Res. 3:1643–1651. 1997.
|
|
15
|
Kenny PA, Lee GY, Myers CA, Neve RM,
Semeiks JR, Spellman PT, Lorenz K, Lee EH, Barcellos-Hoff MH,
Petersen OW, et al: The morphologies of breast cancer cell lines in
three-dimensional assays correlate with their profiles of gene
expression. Mol Oncol. 1:84–96. 2007. View Article : Google Scholar
|
|
16
|
Zhou C, Zhong Q, Rhodes LV, Townley I,
Bratton MR, Zhang Q, Martin EC, Elliott S, Collins-Burow BM, Burow
ME, et al: Proteomic analysis of acquired tamoxifen resistance in
MCF-7 cells reveals expression signatures associated with enhanced
migration. Breast Cancer Res. 14:R452012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Borley AC, Hiscox S, Gee J, Smith C, Shaw
V, Barrett-Lee P and Nicholson RI: Anti-oestrogens but not
oestrogen deprivation promote cellular invasion in intercellular
adhesion-deficient breast cancer cells. Breast Cancer Res.
10:R1032008. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hiscox S, Jiang WG, Obermeier K, Taylor K,
Morgan L, Burmi R, Barrow D and Nicholson RI: Tamoxifen resistance
in MCF7 cells promotes EMT-like behaviour and involves modulation
of beta-catenin phosphorylation. Int J Cancer. 118:290–301. 2006.
View Article : Google Scholar
|
|
19
|
Hutcheson IR, Knowlden JM, Madden TA,
Barrow D, Gee JM, Wakeling AE and Nicholson RI: Oestrogen
receptor-mediated modulation of the EGFR/MAPK pathway in
tamoxifen-resistant MCF-7 cells. Breast Cancer Res Treat. 81:81–93.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kurokawa H, Lenferink AE, Simpson JF,
Pisacane PI, Sliwkowski MX, Forbes JT and Arteaga CL: Inhibition of
HER2/neu (erbB-2) and mitogen-activated protein kinases enhances
tamoxifen action against HER2-overexpressing, tamoxifen-resistant
breast cancer cells. Cancer Res. 60:5887–5894. 2000.PubMed/NCBI
|
|
21
|
Jiang Y, Zhao X, Xiao Q, Liu Q, Ding K, Yu
F, Zhang R, Zhu T and Ge G: Snail and Slug mediate tamoxifen
resistance in breast cancer cells through activation of EGFR-ERK
independent of epithelial-mesenchymal transition. J Mol Cell Biol.
6:352–354. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rabindran SK, Discafani CM, Rosfjord EC,
Baxter M, Floyd MB, Golas J, Hallett WA, Johnson BD, Nilakantan R,
Overbeek E, et al: Antitumor activity of HKI-272, an orally active,
irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res.
64:3958–3965. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sordella R, Bell DW, Haber DA and
Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer
activate anti-apoptotic pathways. Science. 305:1163–1167. 2004.
View Article : Google Scholar : PubMed/NCBI
|
